On July 24, Corcept Therapeutics rose 5.36% in regular trading, trading at $95.755/share, with turnover of $25.46 million.

On the news front, the company has completed the resubmission of its New Drug Application for Relacorilant to treat Cushing's syndrome to the FDA, marking a critical milestone in the drug's path to market approval. This resubmission, initially announced in late May and completed in June, addresses prior regulatory feedback and aims to secure approval for this rare endocrine disorder treatment.

Additionally, the stock is benefiting from anticipation ahead of its upcoming earnings report scheduled for July 29. The company previously issued revenue guidance of $950 million to $1.05 billion, significantly above the FactSet consensus estimate of $899.5 million. Further supporting momentum, the FDA approved Lifyorli (relacorilant) combined with nab-paclitaxel for platinum-resistant ovarian cancer in March, with commercialization now underway.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)